2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Immunology, Autoimmune Disorders, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

2332 On-target CAR T cells as vehicles for effective CD38BiTE delivery overcome antigen escape in multiple myeloma

Jianlin Liu, PhD, Eva Owen2, Ioana Pop3, Kyle Spainhower4, Katarzyna Modzelewska5, Merve Ozdemir6, Steffen Kulp7, Wenxiang Sun8, Anthony D Pomicter, MS9, David Lum10, Birgit Knoechel, MD, PhD11, Jens Lohr12
1 Huntsman Cancer Institute, Salt Lake City, Utah, United States
2 Huntsman Cancer Institute, Salt Lake City, Utah, United States
3 Huntsman Cancer Institute, Salt Lake City, Utah, United States
4 Huntsman Cancer Institute, Salt Lake City, Utah, United States
5 Huntsman Cancer Institute, Salt Lake City, Utah, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Huntsman Cancer Institute, Salt Lake City, Utah, United States
9 Huntsman Cancer Institute, Salt Lake City, Utah, United States
10 Huntsman Cancer Institute, Salt Lake City, Utah, United States
11 Huntsman Cancer Institute, Salt Lake City, Utah, United States
12 Huntsman Cancer Institute, Salt Lake City, Utah, United States

Background: Chimeric antigen receptor (CAR) T cells and antibodies targeting B cell maturation antigen (BCMA) and CD38 have transformed multiple myeloma (MM) therapy. Resistance remains a major challenge, driven partly by antigen escape, and few tumor-selective antigens are therapeutically tractable. BCMA loss, however, is usually subclonal, and expression of both antigens frequently persists or re-emerges after treatment; both therefore remain attractive targets. Because CD38 is also expressed on many healthy tissues, systemic delivery of a CD38-directed engager risks widespread on-target off-tumor toxicity.

Objective: To exploit the recurrent BCMA and CD38 expression in relapsed/refractory MM, we developed a dual-targeting strategy in which anti-BCMA CAR T cells secrete a CD38-targeted bispecific T cell engager (CD38BiTE), enhancing antimyeloma activity and countering subclonal antigen escape while confining CD38BiTE production to the tumor to mitigate the systemic toxicity of CD38-directed therapy.

Methods: We generated αBCMA-CAR.CD38BiTE T cells, with untransduced (UTD), αBCMA-CAR.CD19BiTE, and αCD19-CAR.CD38BiTE as controls. BiTE secretion was confirmed by western blot and by flow cytometry with purified BiTE, which also verified its binding and function. In vitro cytotoxicity against MM.1S cells was evaluated by co-culture and transwell assays with flow cytometry. In vivo, we use a dual-luciferase, two-flank xenograft spatially separating BCMA-positive (BCMApos) and BCMA-negative (BCMAneg) tumors and a marrow-restricted systemic model engrafted with mixed BCMApos and BCMAneg cells to recapitulate heterogeneous antigen expression. CAR T-cell distribution and phenotype were analyzed by flow cytometry, and tumor burden was monitored by bioluminescence imaging.

Results: CD38BiTE-secreting anti-BCMA CAR T cells killed both BCMApos and BCMAneg myeloma cells in vitro. After 16h at an effector-to-target (E:T) ratio of 3:1, αBCMA-CAR.CD19BiTE T cells achieved 45-66% specific lysis (3 donors) through CAR-dependent cytotoxicity alone, whereas αBCMA-CAR.CD38BiTE T cells achieved comparable or higher lysis (51-80%, 3 donors) through cooperative CAR- and BiTE-mediated cytotoxicity; BiTE engagement alone (αCD19-CAR.CD38BiTE) yielded 29-62% (3 donors). At lower E:T ratios (1:1 and 1:3), αBCMA-CAR.CD38BiTE showed comparable or superior to αBCMA-CAR.CD19BiTE. Against BCMAneg MM.1S cells, αCD19-CAR.CD38BiTE and αBCMA-CAR.CD38BiTE mediated comparable CD38-dependent lysis (24h; 3 donors; 16-44% at E:T=1:3, 51-78% at E:T=1:1, 70-90% at E:T=3:1). In transwell assays (E:T = 3:1, 24h, 2 donors), the two CD38BiTE-secreting products killed BCMAneg MM.1S cells comparably when BCMAneg cells were present alone (20% vs 22%), whereas, in the presence of both BCMApos and BCMAneg cells, αBCMA-CAR.CD38BiTE T cells killed significantly more BCMAneg cells than αCD19-CAR.CD38BiTE (27% vs 16%). In the two-flank model with spatially separated BCMApos and BCMAneg tumors, BCMA-targeting CAR T cells preferentially migrated toward, and were retained at, BCMApos tumors. Circulating T cells in blood were less frequent in the CAR.BiTE groups than in the UTD group (0.13% vs 0.78%, day 7, n=3; 0.08% vs 0.88%, endpoint, n=5), and intratumoral analysis showed preferential accumulation in the flank bearing mixed BCMApos and BCMAneg MM.1S cells relative to the BCMAneg-only flank (1.2% vs 0.23%, n=5), with no such bias for UTD T cells (0.05% vs 0.06%, n=5). In the systemic model, BCMA-targeting CAR T cells drove durable regression of established BCMApos tumors, whereas UTD or αCD19-CAR.CD38BiTE T cells allowed progressive growth. Notably, αBCMA-CAR.CD38BiTE T cells also controlled BCMAneg MM.1S tumor growth, outperforming all other groups, including αCD19-CAR.CD38BiTE, indicating that only CD38BiTE secreted by cognate, not irrelevant, CAR T cells reaches levels sufficient for tumor control.

Conclusions: CAR-secreted CD38BiTE potentiates the cytotoxicity of αBCMA-CAR T cells against both BCMApos and BCMAneg myeloma cells. Because these CAR T cells preferentially migrate toward, and are retained at, cognate antigen-expressing tumor, their local accumulation and expansion generate CD38BiTE concentrations sufficient to eliminate BCMAneg cells, an effect not achieved by T cells bearing an irrelevant CAR. By concentrating CD38-directed cytotoxicity at myeloma sites, this strategy counters antigen escape while sparing healthy tissue and limiting systemic toxicity.

Jianlin Liu, PhD: No relevant conflicts of interest to declare.